No evidence to support use of vitamin C supplementation in cancer
the ONA take:
According to a new study published in the journal The Oncologist, researchers have found that there is no high-quality evidence to support the use of ascorbate (vitamin C) supplementation to enhance efficacy or reduce toxicity of chemotherapy in patients with cancer.
For the systematic review, researchers from the Ottawa Hospital Cancer Centre Division of Medical Oncology in Ottawa, Ontario, Canada, sought to investigate whether supplemental ascorbate synergizes the anticancer effects of chemotherapy and reduces its toxicity.
Researchers identified 34 articles to be included in the study from Medline, EMBASE, and the Cochrane central register. Among those, there were five randomized controlled studies, 12 phase 1/2 studies, six observational trials, and 11 case reports.
The studies included a total of over 8,000 patients. Results showed no statistically significant improvements in overall survival or progression-free survival or reduced toxicity with supplemental ascorbate use compared with the control arm.
The authors note that high-quality placebo-controlled studies are needed to assess the effects of ascorbate on chemotherapy efficacy and toxicity in patients with cancer.
No high-quality evidence to support the use of ascorbate (vitamin C) supplementation to enhance cancer treatment.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|